Artificial polyepitope HIV-1 immunogen containing mimotope of 2F5 epitope

Protein and Peptide Letters

Volumn 23, Issue 2, 2016, Pages 159-168

  Shcherbakova, Nadezhda S ^a   Shcherbakov, Dmitry N ^a,b   Bakulina, Anastasiya Yu ^a,c   Karpenko, Larisa I ^a   Ryzhikov, Alexander B ^a   Ilyichev, Alexander A ^a,c  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^b ALTAI STATE UNIVERSITY   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

HIV 1; Humoral response to HIV 1; MAb 2F5; Peptide mimotope; Phage display; Vaccine against HIV 1

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY 2F5; 2F5 MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PROTEIN PURIFICATION; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOGENICITY;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; EPITOPES; HIV-1; HUMANS; MICE; VACCINES, SYNTHETIC;

EID: 84959321585     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: 10.2174/0929866523666151211115746     Document Type: Article

References (62)

1. Griffin, D.E. Immune responses during measles virus infection. In: Measles Virus; Ter Meulen, V.; Billeter, M.A., Eds.; Springer- Verlag: Berlin, 1995; Vol. 191, pp. 117-134.
2. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; Benenson, M.; Gurunathan, S.; Tartaglia, J.; McNeil, J.G.; Francis, D.P.; Stablein, D.; Birx, D.L.; Chunsuttiwat, S.; Khamboonruang, C.; Thongcharoen, P.; Robb, M.L.; Michael, N. L.; Kunasol, P.; Kim, J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med., 2009, 361, 2209-2220.
3. Zhang, Y.; Yuan, T.; Li, J.; Zhang, Y.; Xu, J.; Shao, Y., Chen, Z.; Zhang, M.Y. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. AIDS, 2013, 27, 2529-2539.
4. Pantophlet, R.; Burton, D.R. GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol., 2006, 24, 739-769.
5. Eroshkin, A.M.; Leblanc, A.; Weekes, D.; Post, K.; Li, Z.; Rajput, A.; Butera, S.T.; Burton, D.R.; Godzik, A. BNAber: Database of broadly neutralizing HIV antibodies. Nucleic Acids Res., 2014, 42, D1133-D1139.
6. Montefiori, D.C.; Pantaleo, G.; Fink, L.M.; Zhou, J.T.; Zhou, J.Y.; Bilska, M.; Miralles, G. D.; Fauci, A. S. Neutralizing and infectionenhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis., 1996, 173, 60- 67.
7. Sather, D.N.; Armann, J.; Ching, L.K.; Mavrantoni, A.; Sellhorn, G.; Caldwell, Z.; Yu, X.; Wood, B.; Self, S.; Kalams, S.; Stamatatos, L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol., 2009, 83, 4713-4715.
8. Doria-Rose, N.A.; Klein, R.M.; Manion, M.M.; O'Dell, S.; Phogat, A.; Chakrabarti, B.; Hallahan, C.W.; Migueles, S.A.; Wrammert, J.; Ahmed, R.; Nason, M.; Wyatt, R.T.; Mascola, J.R.; Connors, M. Frequency and phenotype of human immunodeficiency virus envelope- specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol., 2009, 83, 188-199.
9. Simek, M.D.; Rida, W.; Priddy, F.H.; Pung, P.; Carrow, E.; Laufer, D.S.; Lehrman, J.K.; Boaz, M.; Tarragona-Fiol, T.; Miiro, G.; Birungi, J.; Pozniak, A.; McPhee, D. A.; Manigart, O.; Karita, E.; Inwoley, A.; Jaoko, W.; DeHovitz, J.; Bekker, L. G.; Pitisuttithum, P.; Paris, R.; Walker, L. M.; Poignard, P.; Wrin, T.; Fast, P. E.; Burton, D. R.; Koff, W. C. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol., 2009, 83, 7337-7348.
10. Buchacher, A.; Predl, R.; Strutzenberger, K.; Steinfellner, W.; Trkola, A.; Purtscher, M.; Gruber, G.; Tauer, C.; Steindl, F.; Jungbauer, A.; Katinger, H. Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses, 1994, 10, 359-369.
11. Walker, L.M.; Phogat, S.K.; Chan-Hui, P.Y.; Wagner, D.; Phung, P.; Goss, J.L.; Wrin, T.; Simek, M.D.; Fling, S.; Mitcham, J.L.; Lehrman, J.K.; Priddy, F.H.; Olsen, O.A.; Frey, S.M.; Hammond, P.W.; Kaminsky, S.; Zamb, T.; Moyle, M.; Koff, W.C.; Poignard, P.; Burton, D.R.; Protocol, G.P.I. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science, 2009, 326, 285-289.
12. Wu, X.L.; Yang, Z.Y.; Li, Y.X.; Hogerkorp, C.M.; Schief, W.R.; Seaman, M.S.; Zhou, T.Q.; Schmidt, S.D.; Wu, L.; Xu, L.; Longo, N.S.; McKee, K.; O'Dell, S.; Louder, M.K.; Wycuff, D.L.; Feng, Y.; Nason, M.; Doria-Rose, N.; Connors, M.; Kwong, P.D.; Roederer, M.; Wyatt, R.T.; Nabel, G.J.; Mascola, J.R. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.
13. Walker, L.M.; Huber, M.; Doores, K.J.; Falkowska, E.; Pejchal, R.; Julien, J.P.; Wang, S.K.; Ramos, A.; Chan-Hui, P.Y.; Moyle, M.; Mitcham, J.L.; Hammond, P.W.; Olsen, O.A.; Phung, P.; Fling, S.; Wong, C.H.; Phogat, S.; Wrin, T.; Simek, M.D.; Koff, W.C.; Wilson, I.A.; Burton, D.R.; Poignard, P.; Protocol, G.P.I. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 2011, 477, 466-470.
14. Huang, J.; Ofek, G.; Laub, L.; Louder, M.K.; Doria-Rose, N.A.; Longo, N.S.; Imamichi, H.; Bailer, R.T.; Chakrabarti, B.; Sharma, S.K.; Alam, S.M.; Wang, T.; Yang, Y.; Zhang, B.; Migueles, S.A.; Wyatt, R.; Haynes, B.F.; Kwong, P.D.; Mascola, J.R.; Connors, M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012, 491, 406-412.
15. Falkowska, E.; Le, K.M.; Ramos, A.; Doores, K.J.; Lee, J.; Blattner, C.; Ramirez, A.; Derking, R.; vanGils, M.J.; Liang, C.H.; McBride, R.; von Bredow, B.; Shivatare, S.S.; Wu, C.Y.; Chan- Hui, P.Y.; Liu, Y.; Feizi, T.; Zwick, M.B.; Koff, W.C.; Seaman, M. S.; Swiderek, K.; Moore, J.P.; Evans, D.; Paulson, J.C.; Wong, C.H.; Ward, A.B.; Wilson, I.A.; Sanders, R.W.; Poignard, P.; Burton, D.R. Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity, 2014, 40, 657-668.
16. Muster, T.; Steindl, F.; Purtscher, M.; Trkola, A.; Klima, A.; Himmler, G.; Ruker, F.; Katinger, H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol., 1993, 67, 6642-6647.
17. Mascola, J.R.; Lewis, M.G.; Stiegler, G.; Harris, D.; VanCott, T.C.; Hayes, D.; Louder, M.K.; Brown, C.R.; Sapan, C.V.; Frankel, S.S.; Lu, Y.; Robb, M.L.; Katinger, H.; Birx, D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol., 1999, 73, 4009-4018.
18. Mascola, J.R.; Stiegler, G.; VanCott, T.C.; Katinger, H.; Carpenter, C.B.; Hanson, C.E.; Beary, H.; Hayes, D.; Frankel, S.S.; Birx, D.L.; Lewis, M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med., 2000, 6, 207-210.
19. Xu, W.; Hofmann-Lehmann, R.; McClure, H.M.; Ruprecht, R.M. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine, 2002, 20, 1956-1960.
20. Ofek, G.; Tang, M.; Sambor, A.; Katinger, H.; Mascola, J.R.; Wyatt, R.; Kwong, P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol., 2004, 78, 10724-10737.
21. Arnold, G.F.; Velasco, P.K.; Holmes, A.K.; Wrin, T.; Geisler, S.C.; Phung, P.; Tian, Y.; Resnick, D.A.; Ma, X.; Mariano, T.M.; Petropoulos, C.J.; Taylor, J.W.; Katinger, H.; Arnold, E. Broad Neutralization of Human Immunodeficiency Virus Type 1 (HIV-1) Elicited from Human Rhinoviruses That Display the HIV-1 gp41 ELDKWA Epitope. J. Virol., 2009, 83, 5087-5100.
22. Kusov, Y.Y.; Zamjatina, N.A.; Poleschuk, V.F.; Michailov, M.I.; Morace, G.; Eberle, J.; Gauss-Müller, V. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5. Antiviral. Res., 2007, 73, 101-111.
23. McGaughey, G.B.; Citron, M.; Danzeisen, R.C.; Freidinger, R.M.; Garsky, V.M.; Hurni, W.M.; Joyce, J.G.; Liang, X.; Miller, M.; Shiver, J.; Bogusky, M.J. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry, 2003, 42, 3214-23.
24. Venditto, V.J.; Watson, D.S.; Motion, M.; Montefiori, D.; Szoka, F.C. Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination. Clin. Vaccine Immunol., 2013, 20, 39-45.
25. Venditto, V.J.; Wieczorek, L.; Molnar, S.; Teque, F.; Landucci, G.; Watson, D.S.; Forthal, D.; Polonis, V.R.; Levy, J.A.; Szoka, F.C. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitopespecific nonneutralizing antibodies in rabbits. Clin. Vaccine Immunol., 2014, 21, 1086-1093.
26. Ofek, G.; McKee, K.; Yang, Y.; Yang, Z.Y.; Skinner, J.; Guenaga, F.J.; Wyatt, R.; Zwick, M.B.; Nabel, G.J.; Mascola, J.R.; Kwong, P. D. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementaritydetermining region. J. Virol., 2010, 84, 2955-2962.
27. Julien, J.-P.; Bryson, S.; Nieva, J.L.; Pai, E.F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol., 2008, 384, 377-392.
28. Crespillo, S.; Casares, S.; Mateo, P.L.; Conejero-Lara, F. Thermodynamic analysis of the binding of 2F5 (fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity. J. Biol. Chem., 2014, 289, 594- 599.
29. Tudor, D.; Yu, H.F.; Maupetit, J.; Drillet, A.S.; Bouceba, T.; Schwartz-Cornil, I.; Lopalco, L.; Tuffery, P.; Bomsel, M. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc. Natl. Acad. Sci. USA, 2012, 109, 12680-12685.
30. Zhang, Y.; Sagui, C. The gp41(659-671) HIV-1 antibody epitope: a structurally challenging small peptide. J. Phys. Chem. B, 2014, 118, 69-80.
31. Matyas, G.R.; Wieczorek, L.; Beck, Z.; Ochsenbauer-Jambor, C.; Kappes, J.C.; Michael, N.L.; Polonis, V.R.; Alving, C.R. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS, 2009, 23, 2069-2077.
32. Lai, R. P.J.; Hock, M.; Radzimanowski, J.; Tonks, P.; Hulsik, D. L.; Effantin, G.; Seilly, D.J.; Dreja, H.; Kliche, A.; Wagner, R.; Barnett, S.W.; Tumba, N.; Morris, L.; LaBranche, C.C.; Montefiori, D.C.; Seaman, M.S.; Heeney, J.L.; Weissenhorn, W. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J. Biol. Chem., 2014, 289, 29912-26.
33. Ofek, G.; Guenaga, F.J.; Schief, W.R.; Skinner, J.; Baker, D.; Wyatt, R.; Kwong, P.D. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA, 2010, 107, 17880- 17887.
34. Zhai, Y.; Zhong, Z.; Zariffard, M.; Spear, G.T.; Qiao, L. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine, 2013, 31, 5422-5429.
35. Strasz, N.; Morozov, V.A.; Kreutzberger, J.; Keller, M.; Eschricht, M.; Denner, J. Immunization with hybrid proteins containing the membrane proximal external region of HIV-1. AIDS Res. Hum. Retroviruses, 2014, 30, 498-508.
36. Palacios-Rodríguez, Y.; Gazarian, T.; Huerta, L.; Gazarian, K. Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5. Immunol. Lett., 2011, 136, 80-89.
37. Bryson, S.; Julien, J.P.; Hynes, R.C.; Pai, E.F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: Vaccine design implications. J. Virol., 2009, 83, 11862-11875.
38. Menendez, A.; Chow, K.C.; Pan, O.C.C.; Scott, J.K. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitopey. J. Mol. Biol., 2004, 338, 311-327.
39. Eroshkin, A.M.; Karginova, E.A.; Gileva, I.P.; Lomakin, A.S.; Lebedev, L.R.; Kamyinina, T.P.; Pereboev, A.V.; Ignat'ev, G.M. Design of four-helix bundle protein as a candidate for HIV vaccine. Protein Eng., 1995, 8, 167-173.
40. Karpenko, L.I.; Ilyichev, A.A.; Eroshkin, A.M.; Lebedev, L.R.; Uzhachenko, R.V.; Nekrasova, N.A.; Plyasunova, O.A.; Belavin, P A.; Seregin, S.V.; Danilyuk, N.K.; Zaitsev, B.N.; Danilenko, E.D.; Masycheva, V.I.; Bazhan, S.I. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine. Design, immunogenicity and toxicity studies. Vaccine, 2007, 25, 4312-4323.
41. Karpenko, L.; Natalia, R.; Zoya, G.; Vladimir, K.; Sergei, B.; Leonid, L.; Olga, K.; Alena, R.; Alexander, R.; Marina, B.; Svetlana, U.; Valentina, M.; Elena, N.; Alexander, I. Phase I Clinical Trials of DNA-Protein Vaccine (CombiHIVvac) Containing Artificial Multi-Clade Immunogens. AIDS Res. Hum. Retroviruses, 2013, 29, A8-A8.
42. Bazhan, S.I.; Karpenko, L.I.; Lebedev, L.R.; Uzhachenko, R.V.; Belavin, P.A.; Eroshkin, A.M.; Ilyichev, A.A. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- And B-cell epitopes of HIV-1 proteins. Mol. Immunol., 2008, 45, 661-669.
43. Kwong, P.D.; Mascola, J.R.; Nabel, G.J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol., 2013, 13, 693-701.
44. Sparks, D.L.; Page, A.L.; Helmke, P.A.; Loeppert, R.H.; Soltanpour, P.N.; Tabatabai, M.A.; Johnston, C.T.; Summer, M. E. Methods of Soil Analysis. Part3. Chemical Methods.; Soil Science Society of America: Madison, Wisconsin, 1996.
45. Motti, C.; Nuzzo, M.; Meola, A.; Galfré, G.; Felici, F.; Cortese, R.; Nicosia, A.; Monaci, P. Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. Gene, 1994, 146, 191-198.
46. Guex, N.; Peitsch, M.C. SWISS-MODEL and the Swiss- PdbViewer: an environment for comparative protein modeling. Electrophoresis, 1997, 18, 2714-23.
47. Hall, T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser., 1999, 41, 95-98.
48. Smith, G.P.; Scott, J.K. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol., 1993, 217, 228-257.
49. Robertson, G.A.; Kostek, B.M.; Schleif, W.A.; Lewis, J.A.; Emini, E.A. A microtiter cell-culture assay for the determination of antihuman immunodeficiency virus neutralizing antibody activity. J. Virol. Methods, 1988, 20, 195-202.
50. Karpenko, L.I.; Scherbakova, N.S.; Chikaev, A.N.; Tumanova, O.Y.; Lebedev, L.R.; Shalamova, L.A.; Pyankova, O.G.; Ryzhikov, A.B.; Ilyichev, A.A. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12. Mol. Immunol., 2012, 50, 193-199.
51. Montefiori, D.C. Measuring HIV neutralization in a luciferase reporter gene assay. In: HIV Protocols, 2nd ed.; Prasad, V.R.; Kalpana, G.V., Eds.; Humana Press, a part of Springer Science+ Business Media: New York, 2009; Vol. 485, pp. 395-405.
52. Finney, D.J. Probit analysis; a statistical treatment of the sigmoid response curve; Macmillan: Oxford, 1947.
53. Tumanova, O.Y.; Kuvshinov, V.N.; Orlovskaya, I.A.; Pronyaeva, T.R.; Pokrovskii, A.G.; Il'ichev, A.A.; Sandakhchiev, L.S. Immunogenic properties of peptides mimicking a HIV-1 gp41 epitope recognized by virus-neutralizing antibodies 2F5. Mol. Biol., 2003, 37, 473-476.
54. Seaman, M.S.; Janes, H.; Hawkins, N.; Grandpre, L.E.; Devoy, C.; Giri, A.; Coffey, R.T.; Harris, L.; Wood, B.; Daniels, M.G.; Bhattacharya, T.; Lapedes, A.; Polonis, V.R.; McCutchan, F.E.; Gilbert, P.B.; Self, S.G.; Korber, B.T.; Montefiori, D.C.; Mascola, J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol., 2010, 84, 1439-1452.
55. Burton, D.R.; Ahmed, R.; Barouch, D.H.; Butera, S.T.; Crotty, S.; Godzik, A.; Kaufmann, D.E.; McElrath, M.J.; Nussenzweig, M.C.; Pulendran, B.; Scanlan, C.N.; Schief, W.R.; Silvestri, G.; Streeck, H.; Walker, B.D.; Walker, L.M.; Ward, A.B.; Wilson, I.A.; Wyatt, R. A blueprint for HIV vaccine discovery. Cell Host Microbe, 2012, 12, 396-407.
56. Hessell, A.J.; Haigwood, N.L. Neutralizing antibodies and control of HIV: Moves and countermoves. Curr. HIV/AIDS Rep., 2012, 9, 64-72.
57. Yi, G.; Lapelosa, M.; Bradley, R.; Mariano, T.M.; Dietz, D.E.; Hughes, S.; Wrin, T.; Petropoulos, C.; Gallicchio, E.; Levy, R.M.; Arnold, E.; Arnold, G.F. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses. PloS One, 2013, 8, e72205-e72205.
58. Kumar, A.; Kumar, V.; Shukla, G.C.; Rao, K.V.S. Immunological characteristics of a recombinant hepatitis B virus-derived multipleepitope polypeptide: a study in polyvalent vaccine design. Vaccine, 1994, 12, 259-266.
59. Bouche, F.B.; Steinmetz, A.; Yanagi, Y.; Muller, C.P. Induction of broadly neutralizing antibodies against measles virus mutants using a polyepitope vaccine strategy. Vaccine, 2005, 23, 2074-2077.
60. Cai, Q.; Peng, G.; Bu, L.; Lin, Y.; Zhang, L.; Lustigmen, S.; Wang, H. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling. Vaccine, 2007, 25, 5155-5165.
61. Karpenko, L.I.; Danilenko, A.V.; Bazhan, S.I.; Danilenko, E.D.; Sysoeva, G.M.; Kaplina, O.N.; Volkova, O.Y.; Oreshkova, S.F.; Ilyichev, A.A. Attenuated Salmonella enteritidis E23 as a vehicle for the rectal delivery of DNA vaccine coding for HIV-1 polyepitope CTL immunogen. Microb. Biotechnol., 2012, 5, 241-250.
62. Li, M.; Gao, F.; Mascola, J.R.; Stamatatos, L.; Polonis, V.R.; Koutsoukos, M.; Voss, G.; Goepfert, P.; Gilbert, P.; Greene, K.M.; Bilska, M.; Kothe, D.L.; Salazar-Gonzalez, J.F.; Wei, X.; Decker, J.M.; Hahn, B.H.; Montefiori, D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol., 2005, 79, 10108-10125..